Derry C J, Harper N, Davies D H, Murphy J J, Staines N A
Division of Life Sciences, King's College London, UK.
Arthritis Rheum. 2001 Aug;44(8):1917-27. doi: 10.1002/1529-0131(200108)44:8<1917::AID-ART330>3.0.CO;2-W.
To determine the influence of the dose of collagen given nasally on the induction of specific mucosal tolerance in collagen-induced arthritis.
The severity of clinical arthritis induced in DBA/1 mice was studied after the nasal administration (before disease induction) of 1 of 4 doses (across a 2-log range) of bovine type II collagen (CII). Parameters of immunity included lymphocyte proliferation and cytokine production in vitro in response to antigen stimulation, and the production of anticollagen IgG antibody subclasses.
The 3 highest doses (20, 80, and 320 microg) ameliorated disease severity, whereas the lowest dose (5 microg) aggravated disease. These findings correlated well with antigen-specific T cell proliferation and cytokine and antibody production. T cell proliferation was suppressed by the higher doses of CII, whereas the low dose enhanced T cell proliferation, indicating it primed the T cells. Suppression of T cell proliferation could be overcome by the addition of exogenous interleukin-2 (IL-2) to these cultures. Decreased T cell proliferation was associated with suppression of both Th1 (interferon-gamma [IFNgamma]) and Th2 (IL-4) cytokines and all the subclasses of anticollagen IgG in mice receiving 20, 80, or 320 microg of collagen. Overall, the highest dose of collagen (320 microg) was less effective at suppressing the immune response and disease than the 20-microg or 80-microg doses. There was an increased production of antibodies of all IgG isotypes, and of the Th1-associated cytokines IFNgamma and IL-2, in animals that had received the lowest dose of 5 microg collagen nasally.
Nasal administration of antigens is effective in inducing tolerance and reducing disease severity, but the effects are dose dependent. Low doses can prime the immune system and aggravate disease; high doses may not suppress disease. Suppression of the immune response, which correlates with suppression of disease, is not obviously associated with a type I to type II T cell switch, but rather with an overall suppression of both forms of T cell response, with a potential role for anergy of T cells in this process.
确定经鼻给予胶原蛋白剂量对胶原诱导性关节炎中特异性黏膜耐受诱导的影响。
在DBA/1小鼠经鼻给予(疾病诱导前)4种剂量(跨越2个对数范围)的牛II型胶原蛋白(CII)中的1种后,研究诱导的临床关节炎严重程度。免疫参数包括体外淋巴细胞增殖和对抗原刺激的细胞因子产生,以及抗胶原蛋白IgG抗体亚类的产生。
3个最高剂量(20、80和320微克)减轻了疾病严重程度,而最低剂量(5微克)加重了疾病。这些发现与抗原特异性T细胞增殖以及细胞因子和抗体产生密切相关。较高剂量的CII抑制T细胞增殖,而低剂量增强T细胞增殖,表明其使T细胞致敏。在这些培养物中添加外源性白细胞介素-2(IL-2)可克服T细胞增殖的抑制。在接受20、80或320微克胶原蛋白的小鼠中,T细胞增殖减少与Th1(干扰素-γ [IFNγ])和Th2(IL-4)细胞因子以及抗胶原蛋白IgG的所有亚类的抑制有关。总体而言,最高剂量的胶原蛋白(320微克)在抑制免疫反应和疾病方面不如20微克或80微克剂量有效。在经鼻接受最低剂量5微克胶原蛋白的动物中,所有IgG同种型抗体以及与Th1相关的细胞因子IFNγ和IL-2的产生均增加。
经鼻给予抗原可有效诱导耐受并降低疾病严重程度,但效果呈剂量依赖性。低剂量可使免疫系统致敏并加重疾病;高剂量可能无法抑制疾病。免疫反应的抑制与疾病的抑制相关,这与I型到II型T细胞转换无明显关联,而是与两种形式的T细胞反应的总体抑制有关,在此过程中T细胞无反应性可能发挥作用。